Drug Discovery and Development Solutions for Pancreatic Cancer

Our In Vitro Efficacy Testing Service accelerates pancreatic cancer drug discovery by providing robust, sensitive platforms for screening compounds, biologics, and immunotherapies. We evaluate key targets including PARP, PD-1/PD-L1, EGFR, and somatostatin receptors using advanced biochemical, cell-based, and biophysical assays. Employing methods such as ATP, chemiluminescence, flow cytometry, FACS, and surface plasmon resonance, we deliver precise measurements of potency, affinity, and efficacy (IC-50, EC-50, Kd, pEC-50). Our comprehensive profiling of drug candidates supports lead optimization, risk assessment, and effective selection, driving development of innovative therapies for pancreatic cancer.

Alfa Cytology provides comprehensive pancreatic cancer animal model development, leveraging 105 validated models across five species and 26 strains. We offer xenograft, orthotopic, PDX, GEMM, syngeneic, and organoid-based models, supporting rapid, reproducible, and translational research. Our services include customized model establishment, advanced imaging, tumor monitoring, drug administration, and detailed molecular and histopathological analyses. Key endpoints encompass tumor growth, metastasis, survival, biomarker expression, and immune profiling. With rigorous quality control, expert staff, and flexible study design, we deliver actionable data to accelerate therapeutic discovery and enable confident preclinical evaluation for pancreatic cancer research.

Our PK/PD research service for pancreatic cancer delivers comprehensive analysis of drug absorption, distribution, metabolism, and elimination, integrating advanced modeling with robust experimental data. We offer diverse administration routes and detailed compartment analysis across key tissues, utilizing cutting-edge analytical methods such as HPLC, LC-MS, ELISA, and radioactivity assays. Employing a wide range of animal models, we ensure translational relevance and predictive accuracy. Our data-driven approach supports candidate selection, dosing optimization, and clinical trial design, providing essential insights that accelerate the development of effective, targeted therapies for pancreatic cancer through rigorous, tailored PK/PD studies.

Alfa Cytology delivers comprehensive toxicity assessment services tailored to pancreatic cancer therapeutics, integrating acute, chronic, organ-specific, and systemic evaluations. Utilizing advanced analytical technologies, validated in vivo models, and disease-specific endpoints, we provide robust data on safety profiles. Our methodologies encompass high-throughput clinical chemistry, digital pathology, and behavioral analysis, ensuring precise and reproducible results. Studies are conducted under strict regulatory compliance, supporting global drug development and regulatory submissions. With expert oncology collaboration, we address unique safety challenges, enabling informed decision-making, risk mitigation, and accelerated advancement of novel pancreatic cancer candidates toward clinical success and improved patient outcomes.

We offer advanced biomarker analysis services for pancreatic cancer research, employing multi-omics discovery strategies that integrate genomics, transcriptomics, proteomics, and metabolomics. Our team explores and screens candidate molecules with potential as biomarkers, utilizing high-throughput screening, in vitro and in vivo models, and diverse analytical platforms such as immunoassays, mass spectrometry, flow cytometry, and molecular diagnostics. We assess potential biomarker expression, relevance, and disease association, supporting preclinical drug discovery. Our expertise lies in evaluating and characterizing biomarker candidates, providing rigorous, data-driven insights while maintaining scientific objectivity throughout all research and preclinical stages.